Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2013.786070 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC.
Front Immunol
December 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Background: The use of programmed death-1 (PD-1) inhibitors in the neoadjuvant setting for patients with resectable stage III NSCLC has revolutionized this field in recent years. However, there is still 40%-60% of patients do not benefit from this approach. The complex interactions between immune cell subtypes and tertiary lymphoid structures (TLSs) within the tumor microenvironment (TME) may influence prognosis and the response to immunochemotherapy.
View Article and Find Full Text PDFEnhanced Prenatal and Postnatal Development Study in Marmoset Monkeys Following Administration of Felzartamab.
Int J Toxicol
December 2024
Human Immunology Biosciences, Inc., South San Francisco, CA, USA.
Felzartamab is a recombinant fully human immunoglobulin G1 anti-CD38 monoclonal antibody under clinical investigation for immune-mediated diseases. In support of felzartamab clinical development, toxicology studies were conducted in marmoset monkeys, which was the most relevant species based on CD38 binding affinity, pharmacologic activity, and target expression. The felzartamab toxicology program included an enhanced prenatal and postnatal development (ePPND) study to identify potential reproductive and postnatal development risks.
View Article and Find Full Text PDFModelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients.
Sci Rep
October 2024
Institute for Computational Biomedicine-Disease Modeling, RWTH Aachen University, Aachen, Germany.
Acute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming (hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many patients eventually relapse. The "7+3 regimen", which consists of 7 days of cytarabine in combination with daunorubicin during the first 3 days, is a widely used therapy protocol.
View Article and Find Full Text PDFCytofluorometric assessment of calreticulin exposure on CD38 plasma cells from the human bone marrow.
Methods Cell Biol
October 2024
Apoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, Zaragoza, Spain. Electronic address:
Article Synopsis
- Exposure of calreticulin (CALR) on the surface of stressed and dying cells is crucial for their effective uptake by antigen-presenting cells like dendritic cells, aiding in the adaptive immune response and memory formation.
- In contrast, the presence of phosphatidylserine (PS) signals tolerogenic macrophages for quick engulfment of dying cells, highlighting different immune responses.
- The article outlines a protocol for using flow cytometry to measure CALR and PS on plasma cells in multiple myeloma patients, and suggests this method can be adapted for use with other cancers as well.
Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few real-world data exist on its use in patients with myeloma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!